Which CLL drug gives best bang for the buck? new study analyzes costs and patient Well-Being

NCT ID NCT02414022

Ongoing Knowledge-focused Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. The goal is to help public health systems decide which treatment offers the best value.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ibrutinib, rituximab, bendamustine
What this could lead to: If successful, this could help healthcare systems decide which treatment offers the best value for money in older CLL patients.
What could go wrong: This is an economic analysis of a small subset of patients, not a new treatment trial. Results may not apply to all patients or healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Allan Blair Cancer Centre

Regina, Saskatchewan, Canada
CHUM-CEntre Hospitalier de l'Universite de Montreal

Montreal, Quebec, Canada
CSSS Champlain-Charles LeMoyne

Greenfield Park, Quebec, Canada
Health Sciences North

Greater Sudbury, Ontario, Canada
Humber River Hospital

Toronto, Ontario, Canada
Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Ontario, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L3N6, Canada
London Regional Cancer Program

London, Ontario, Canada
Odette Cancer Centre Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, Canada
Stronach Regional Health Centre at Southlake

Newmarket, Ontario, L3Y 2P9, Canada
The Jewish General Hospital

Montreal, Quebec, Canada
The Moncton Hospital

Moncton, New Brunswick, Canada
Tom Baker Cancer Centre

Calgary, Alberta, Canada
University Health Network Princess Margaret Cancer Centre

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.